highperformr logo

Apexigen's Overview

Total employees11
HeadquartersSan Carlos
Founded

Apexigen was a clinical-stage biopharmaceutical company that focused on the discovery and development of innovative antibody therapeutics for oncology. Their proprietary APXiMAB™ antibody discovery platform was designed to generate a diverse range of humanized monoclonal antibodies with the potential to activate the immune system or directly target tumor cells. Key pipeline candidates included sotigalimab (a CD40 agonist) and APX601 (a TNFR2 antagonist). In August 2023, Apexigen was acquired by Pyxis Oncology, Inc. This profile reflects Apexigen's operations and status prior to and leading up to its acquisition.

Where is Apexigen's Headquarters?

Apexigen officeApexigen officeApexigen officeApexigen office
*Images sourced via web search. Rights belong to original owners

HQ Function

The headquarters served as the central hub for Apexigen's research and development, clinical trial management, and corporate operations, focusing on advancing its pipeline of antibody-based cancer therapies.

Notable Features:

Located in a biotech-focused business park, the facility likely featured specialized laboratory spaces for antibody discovery and preclinical development, alongside office facilities for clinical, regulatory, and administrative teams.

Work Culture:

As a clinical-stage biopharmaceutical company, the work culture at Apexigen likely emphasized scientific rigor, innovation, collaboration, and a strong sense of mission towards developing new cancer treatments. It would have been a dynamic and fast-paced environment driven by research milestones and clinical development timelines.

HQ Significance:

The San Carlos headquarters was significant as the epicenter of Apexigen's efforts to leverage its APXiMAB™ platform and develop novel immunotherapies, contributing to the broader biotech ecosystem in the Bay Area before its acquisition.

Values Reflected in HQ: The headquarters operations likely reflected values of scientific excellence, innovation in drug discovery, a commitment to addressing unmet medical needs in oncology, and urgency in advancing potential therapies.

Location:

Prior to its acquisition by Pyxis Oncology, Apexigen's global presence was primarily characterized by its clinical trial activities. While its physical R&D and corporate operations were centered in the United States, its clinical studies for drug candidates like sotigalimab often involved trial sites, investigators, and collaborations in multiple countries. This was necessary to ensure diverse patient populations and meet global regulatory standards for drug development, rather than maintaining a network of international offices.

Street Address:

75 Shoreway Road, Suite C

City:

San Carlos

State/Province:

CA

Country:

USA

Apexigen's Global Presence

N/A - Primarily operated from San Carlos, CA

Address: N/A

The company's focus was on leveraging the biotech ecosystem of the San Francisco Bay Area from its primary location.

Buying Intent Signals for Apexigen

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Executive Team of Apexigen

As of April 2025, Apexigen' leadership includes:

Xiaodong Yang, M.D., Ph.D. - President and Chief Executive Officer (Former)
Ovid Trifan, M.D., Ph.D. - Chief Medical Officer (Former)
Francis Sarena, Ph.D. - Chief Operating Officer (Former)
William L. Largent - Interim Chief Financial Officer (Former, leading up to acquisition)

Investors of Apexigen

Apexigen has been backed by several prominent investors over the years, including:

Decheng Capital
SVB Leerink (now SVB Securities)
Boxer Capital (of the Tavistock Group)
OrbiMed
Frazier Healthcare Partners
Logos Capital
Pivotal bioVenture Partners China

Executive New Hires/Exits in the Last 12 Months

Hire0
Exits4

The most significant executive event for Apexigen was its acquisition by Pyxis Oncology, completed in August 2023. This event led to the transition and departure of the Apexigen executive team as the company was integrated into Pyxis Oncology. There were no new executive hires into Apexigen's standalone leadership in its final months.

Departures

Xiaodong Yang, M.D., Ph.D., Departed role at Apexigen following its acquisition by Pyxis Oncology.
Ovid Trifan, M.D., Ph.D., Departed role at Apexigen following its acquisition by Pyxis Oncology.
Francis Sarena, Ph.D., Departed role at Apexigen following its acquisition by Pyxis Oncology.
William L. Largent, Concluded role as Interim CFO at Apexigen following its acquisition by Pyxis Oncology.

Technology (Tech Stack) used by Apexigen

Discover the tools Apexigen uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Apexigen Email Formats and Examples

Prior to its acquisition by Pyxis Oncology, Apexigen, Inc. likely utilized common corporate email formats. Based on patterns observed for similar biotech companies, a frequently used format was the first initial followed by the last name. The success rate is an estimated historical figure and is not applicable currently.

(first_initial)(last)@apexigen.com

Format

jdoe@apexigen.com

Example

75%

Success rate

News and media

GlobeNewswire (Pyxis Oncology)August 8, 2023

Pyxis Oncology Completes Acquisition of Apexigen

Pyxis Oncology announced the successful completion of its acquisition of Apexigen, Inc. This strategic move aimed to enhance Pyxis's pipeline with Apexigen's antibody therapeutics, notably sotigalimab, a CD40 agonist....more

GlobeNewswire (Apexigen, Inc.)August 4, 2023

Apexigen Announces Stockholder Approval of Merger Agreement with Pyxis Oncology

Apexigen, Inc. announced that its stockholders voted to approve the previously announced merger agreement with Pyxis Oncology, a critical step towards the finalization of the acquisition....more

GlobeNewswire (Pyxis Oncology/Apexigen)May 10, 2023

Pyxis Oncology to Acquire Apexigen, Strengthening Leadership in Antibody-Drug Conjugates and Immuno-Oncology

Pyxis Oncology and Apexigen jointly announced they had entered into a definitive agreement for Pyxis to acquire Apexigen. The transaction was intended to combine their expertise and pipelines in oncology....more

Highperformr’s free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Apexigen, are just a search away.